Key Figures Q4/Full Year 2019
|
SEK m, unless otherwise stated |
2019 Oct-Dec |
2018 Oct-Dec |
2019 Jan-Dec |
2018 Jan-Dec |
Δ 2018-2019 |
|
Net revenues |
238.1 |
227.1 |
844.8 |
783.1 |
8% |
|
whereof Zubsolv® US net revenues |
190.5 |
166.7 |
719.2 |
621.5 |
16% |
|
Cost of goods sold |
-23.0 |
-43.4 |
-105.6 |
-171.8 |
-39% |
|
Operating expenses |
-143.5 |
-146.1 |
-508.0 |
-515.6 |
-1% |
|
EBIT |
71.5 |
37.6 |
231.2 |
95.8 |
141% |
|
EBIT margin, % |
30.0 |
16.6 |
27.4 |
12.2 |
15.2 ppt |
|
US EBIT |
98.2 |
62.0 |
350.9 |
198.3 |
77% |
|
US EBIT margin, % |
51.6 |
37.2 |
48.8 |
31.9 |
16.9 ppt |
|
EBITDA |
85.8 |
42.8 |
272.1 |
116.6 |
133% |
|
Earnings per share, before dilution, SEK |
1.12 |
1.49 |
6.33 |
3.99 |
59% |
|
Earnings per share, after dilution, SEK |
1.10 |
1.47 |
6.20 |
3.93 |
58% |
|
Cash flow from operating activities |
60.2 |
71.7 |
290.9 |
242.0 |
20% |
|
Cash and cash equivalents |
816.8 |
589.8 |
816.8 |
589.8 |
38% |
Distribution of Net Revenues Q4/Full Year 2019
|
SEK m |
2019 Oct-Dec |
2018 Oct-Dec |
2019 Jan-Dec |
2018 Jan-Dec |
|
Zubsolv® US |
190.5 |
166.7 |
719.2 |
621.5 |
|
Zubsolv - ex US |
0.0 |
5.2 |
0.1 |
36.2 |
|
Zubsolv – total |
190.5 |
171.9 |
719.3 |
657.8 |
|
Abstral® royalties |
46,2 |
52.4 |
112.6 |
118.8 |
|
Edluar® royalties |
1.3 |
2.9 |
11.6 |
6.6 |
|
OX-MPI |
0.0 |
- |
1.4 |
- |
|
Total |
238.1 |
227.1 |
844.8 |
783.1 |
Cash flow Q4/Full Year 2019
|
SEK m |
2019 Oct-Dec |
2018 Oct-Dec |
2019 Jan-Dec |
2018 Jan-Dec |
|
Cash flow from operating activities |
60.2 |
71.7 |
290.9 |
242.0 |
|
Investment activities |
-11.0 |
-3.9 |
-26.3 |
-6.2 |
|
Financing activities |
-4.3 |
0.0 |
-53.7 |
0.0 |
|
Cash flow (excl exchange rate differences) |
44.8 |
67.8 |
210.8 |
235.8 |
|
Liquid funds |
816.8 |
589.8 |
816.8 |
589.8 |
